首页|羟苯磺酸钙联合阿柏西普玻璃体腔内注射治疗糖尿病视网膜病变的效果

羟苯磺酸钙联合阿柏西普玻璃体腔内注射治疗糖尿病视网膜病变的效果

扫码查看
目的:观察糖尿病视网膜病变患者采取羟苯磺酸钙联合阿柏西普玻璃体腔内注射治疗的效果。方法:选取2019 年 6 月—2022 年 3 月于苏州市相城人民医院就诊的 92 例糖尿病视网膜病变患者作为研究对象,采用随机数表法将患者分为常规组(46 例,阿柏西普玻璃体腔内注射治疗)与研究组(46 例,羟苯磺酸钙联合阿柏西普玻璃体腔内注射治疗)。比较两组治疗前及治疗后 1 个月、2 个月、3 个月后最佳矫正视力(BCVA)、5 mm直径范围内黄斑视网膜体积(TMV)、黄斑中心凹厚度(CMT),比较两组临床疗效、不良反应。结果:两组治疗后 1 个月、2 个月、3 个月BCVA、TMV优于治疗前,治疗后 2 个月、3 个月BCVA、TMV优于治疗后 1 个月,且研究组治疗后 1 个月、2 个月、3 个月BCVA高于常规组,TMV低于常规组,差异有统计学意义(P<0。05)。两组治疗后 1 个月、2 个月、3 个月CMT低于治疗前,治疗后 2 个月、3 个月CMT低于治疗后 1 个月,治疗后 3 个月CMT低于治疗后 2 个月,且研究组治疗后 1 个月、2 个月、3 个月CMT低于常规组,差异有统计学意义(P<0。05)。研究组总有效率高于常规组,差异有统计学意义(P<0。05)。两组不良反应发生率比较,差异无统计学意义(P>0。05)。结论:糖尿病视网膜病变患者采取羟苯磺酸钙联合阿柏西普玻璃体腔内注射治疗效果显著,可改善视力及黄斑水肿,且安全可靠。
Effect of Calcium Dobesilate Combined with Aflibercept Intravitreal Injection in the Treatment of Diabetic Retinopathy
Objective:To observe the effect of Calcium Dobesilate combined with Aflibercept intravitreal injection in the treatment of patients with diabetic retinopathy.Method:A total of 92 patients with diabetic retinopathy who treated in Suzhou Xiangcheng People's Hospital from June 2019 to March 2022 were selected as the research objects,the patients were divided into the conventional group(46 cases,Aflibercept intravitreal injection)and the study group(46 cases,Calcium Dobesilate combined with Aflibercept intravitreal injection)by random number table method.The best corrected visual acuity(BCVA),macular retinal volume(TMV)and central macular thickness(CMT)in the 5 mm diameter range were compared between two groups before treatment and 1 month,2 months and 3 months after treatment,the clinical efficacy and adverse reactions were compared between two groups.Result:The BCVA and TMV of two groups at 1 month,2 months and 3 months after treatment were better than those before treatment,and the BCVA and TMV at 2 months and 3 months after treatment were better than those at 1 month after treatment,the BCVA of the study group at 1 month,2 months and 3 months after treatment was higher than those of the conventional group,and the TMV were lower than those of the conventional group,the differences were statistically significant(P<0.05).The CMT of two groups at 1 month,2 months and 3 months after treatment were lower than those before treatment,the CMT at 2 months and 3 months after treatment were lower than those at 1 month after treatment,the CMT at 3 months after treatment were lower than those at 2 months after treatment,the CMT of the study group at 1 month,2 months and 3 months after treatment were lower than those of the conventional group,the differences were statistically significant(P<0.05).The total effective rate of the study group was higher than that of the conventional group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Calcium Dobesilate combined with Aflibercept intravitreal injection is effective in patients with diabetic retinopathy,which can improve vision and macular edema,and is safe and reliable.

Diabetic retinopathyCalcium DobesilateAfliberceptMacular fovea thicknessMacular edema

黄晖、蔡琴华、崔宇辉

展开 >

苏州市相城人民医院 江苏 苏州 215131

苏州大学附属第一人民医院

糖尿病视网膜病变 羟苯磺酸钙 阿柏西普 黄斑中心凹厚度 黄斑水肿

2024

中外医学研究
中国医院管理杂志社

中外医学研究

影响因子:1.149
ISSN:1674-6805
年,卷(期):2024.22(14)
  • 20